Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel Group Trial Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes Using Basal-bolus Insulin Injection Therapy

NCT01686620 is registered in ClinicalTrials.gov with Biodel as lead sponsor.

NCT NCT01686620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01686620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel Group Trial Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes Using Basal-bolus Insulin Injection Therapy
Lead sponsor
Biodel
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
June 30, 2013
Enrollment
132 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus